ADRX — ADARx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802369 ·
Last close
$13.82
Market Cap
$1.53B
52W High
$23.21
52W Low
$12.50
ADV30
446,716
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,217,000 | — | -32,177,000 | -28,117,000 | 929,064,000 | 570,610,000 | 354,662,000 |
| Jun 2026 | 746,000 | — | -29,891,000 | -25,759,000 | 456,332,000 | 58,484,000 | 707,384,000 |
| Mar 2026 | 2,140,000 | — | -27,056,000 | -22,667,000 | 482,558,000 | 63,858,000 | 708,290,000 |
| Dec 2025 | — | — | — | — | 507,655,000 | 66,517,000 | 709,910,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$250,868,000
Investing CF
$-207,501,000
Financing CF
$91,000
CapEx
$-1,933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-269,125,000
Inventory
—
Receivables
—
ST Investments
$368,768,000
EBIT TTM
$-95,957,000
Pretax Income TTM
$-82,070,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,127,000
EBITDA
$-105,124,000
Free Cash Flow
—
Enterprise Value
$1,450,645,888
Total Cash
$427,252,000
Total Debt
$6,898,000
Shares Out
110,738,825
Trailing EPS
$-1.16
Book Value
$-22.16
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,449,000 | -88,365,000 | -73,088,000 | 507,655,000 | 709,910,000 | -202,255,000 | 262,288,000 |
| Dec 2024 | 0 | -58,233,000 | -46,360,000 | 233,454,000 | 370,599,000 | -137,145,000 | -48,563,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.51
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | $1.54B | $4.29 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.56B | $14.24 | — |
| KRSA | Korsana Biosciences, Inc. | $1.48B | $32.50 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.58B | $14.77 | — |
| KLRA | Kailera Therapeutics, Inc. | $1.58B | $12.20 | — |
News headlines (Yahoo Finance, 1h cache)
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 21:05 · Yahoo
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
2026-11-09 13:00 · Yahoo
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
2026-10-01 20:15 · Yahoo
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
2026-09-28 03:10 · Yahoo
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
2026-09-24 23:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.